Data gathered: November 27
Alternative Data for NovaBay Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 75 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1 | Sign up | Sign up | Sign up |
| Facebook Followers | 4,261 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 19,805 | Sign up | Sign up | Sign up |
| Twitter Followers | 4,181 | Sign up | Sign up | Sign up |
| Twitter Mentions | 100 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 129 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 34 | Sign up | Sign up | Sign up |
| Linkedin Employees | 68 | Sign up | Sign up | Sign up |
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally.
| Price | $0.59 |
| Target Price | Sign up |
| Volume | 85,970 |
| Market Cap | $3M |
| Year Range | $0.38 - $6.1 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.comNovember 26 - ETF Daily News |
 |
NovaBay Pharmaceuticals Stockholders Fail to Approve Asset Sale and Dissolution Proposal at Special MeetingNovember 24 - ETF Daily News |
 |
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024November 22 - Yahoo |
 |
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.comNovember 18 - ETF Daily News |
 |
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova BrandNovember 14 - Yahoo |
|
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.comNovember 12 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 2.4M | 3.5M | 1.6M | -1.2M | -1.2M | -0.330 |
| Q2 '24 | 2.4M | 3.4M | 1.6M | -1.6M | -1M | -1.370 |
| Q1 '24 | 1.8M | 4.2M | 1.8M | -3.2M | -1.6M | -0.150 |
| Q4 '23 | 3.2M | 7.2M | 1.8M | -4.1M | -3.4M | -1.330 |
| Q3 '23 | 3.3M | 4.4M | 1.7M | -1.8M | -1.1M | -0.370 |
Insider Transactions View All
| Kunin Jeffrey filed to sell 1 shares at $2.1. December 5 '22 |
Similar companies
Read more about NovaBay Pharmaceuticals (NBY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of NovaBay Pharmaceuticals?
The Market Cap of NovaBay Pharmaceuticals is $3M.
What is the current stock price of NovaBay Pharmaceuticals?
Currently, the price of one share of NovaBay Pharmaceuticals stock is $0.59.
How can I analyze the NBY stock price chart for investment decisions?
The NBY stock price chart above provides a comprehensive visual representation of NovaBay Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling NovaBay Pharmaceuticals shares. Our platform offers an up-to-date NBY stock price chart, along with technical data analysis and alternative data insights.
Does NBY offer dividends to its shareholders?
As of our latest update, NovaBay Pharmaceuticals (NBY) does not offer dividends to its shareholders. Investors interested in NovaBay Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of NovaBay Pharmaceuticals?
Some of the similar stocks of NovaBay Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.